ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Challenges Use Of Avastin In UK To Treat Eye Disease

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Swiss drug maker Novartis (NVS) is challenging the use of a unlicensed cheaper medicine to treat an eye disease in the U.K. as an alternative to its drug Lucentis. "It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available," Novartis said in a statement. "It undermines the regulatory process that was introduced to safeguard patients." Novartis also said there is "emerging evidence" of potential safety concerns on the use of Avastin, or bevacizumab, to treat a neovascular form of age related macular degeneration, known as wet AMD. The BBC Tuesday said Novartis was seeking a judicial review of the policy to pay for Avastin on the publicly funded National Health Service, after the NHS in four areas in the south of England agreed last year that Avastin could be prescribed for the condition. Novartis declined to comment on whether it was seeking the review. Lucentis, Novartis' best-selling eye drug which generated $2.05 billion in sales in 2011, is recommended for use by the NHS to treat wet age-related macular degeneration. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
05/23/201512:03:02Billionaire George Soros Just Sold These 3 Stocks: Should You?
05/23/201509:09:02Will Competition Cause Teva Pharmaceutical Industries ltd. To...
05/17/201513:02:02Could This Be Healthcare's $158 Billion Black Swan Event?
05/17/201509:05:022 Stocks With Jaw-Dropping Growth Potential
05/12/201510:26:025 Largest Markets for Pharmaceuticals
05/11/201511:40:11Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/08/201515:04:02GlaxoSmithKline PLC Earnings: Pay No Attention to the Results...
05/08/201511:12:03The Best Fidelity Mutual Funds
05/07/201513:40:20Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/07/201513:34:24Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/06/201518:01:31ADR Shares End Mixed; Anheuser-Busch InBev Rises
05/06/201508:50:06GSK Cuts Return to Holders From Novartis Asset Swap
05/06/201507:58:20Genmab 1Q Sales of Arzerra Leukaemia Drug at GBP11.1 Million
05/04/201519:22:23Generic Drugs Grab Growing Market Share in Mexico--Update
05/04/201519:22:11Generic Drugs Grab Market Share in Mexico
05/04/201511:57:01Why Shares in Array BioPharma, Inc. Are Soaring Higher
05/02/201510:41:02The Best Way to Invest Money in Silicon Valley
05/01/201514:49:19Waiting for Exelixis, Inc.'s Meteor to Land
04/30/201513:47:19Teva Pharmaceutical Industries Ltd Posts Solid Quarter, Stays...
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad